How lung cancer screening reshapes the public health agenda years after quitting smoking

When Quitting Smoking No Longer Means "No Risk"

In July 2026, *The New York Times* reported on a man who, nearly two decades after quitting smoking, was found to have early-stage lung cancer through a routine low-dose CT scan and successfully underwent curative surgery. The story seemed like a model of personal health, but it touches on a long-underestimated structural issue: the lung cancer risk for ex-smokers does not linearly decline to zero over time, and existing public health screening guidelines often fail to adequately cover this group.

In Western developed countries, smoking rates have steadily declined over the past three decades, yet lung cancer remains the leading cause of cancer death. Since 2021, the U.S. Preventive Services Task Force (USPSTF) has lowered the starting age for lung cancer screening to 50, reduced the pack-year smoking history threshold to 20 pack-years, and incorporated years since quitting into the assessment—marking an extension of screening logic from "current smokers" to "those with a smoking history." The protagonist in the above report is a typical beneficiary of this policy adjustment.

Low-Dose CT: From Luxury to Public Good

The large-scale deployment of low-dose spiral CT technology is the material foundation for this change. Over the past decade, the cost of a single CT scan has dropped by more than 40% in developed countries, and the radiation dose is only one-tenth that of a traditional CT, making annual screening economically feasible. More importantly, AI-assisted reading systems have increased nodule detection rates by over 15% while reducing false-positive anxiety.

Behind this lies a global medical infrastructure race: Japan incorporated lung cancer screening into its national health plan as early as the 2010s; South Korea achieved mobile CT van coverage in rural areas in 2020; and China, under the "Healthy China 2030" strategy, has made low-dose CT a standard device in county-level hospitals. The collapse of technology costs and the embedding of AI are transforming lung cancer screening from an "elite health check" into an "accessible public good."

Policy Lag and Structural Gaps

However, the global rollout of screening still faces severe imbalances. The World Health Organization estimates that in low-income countries, more than 70% of lung cancer cases are diagnosed at an advanced stage, and early screening is virtually nonexistent. Even in developed countries, compliance rates remain low: only about 30% of eligible individuals in the U.S. undergo annual screening. The reasons are multifaceted—primary care physicians' lagging awareness, excessive fear of radiation, and fragmented insurance coverage.

A deeper issue is that current screening models are primarily based on "smoking history," ignoring the rising incidence of lung cancer among never-smokers (especially in East Asian women). This means that a one-size-fits-all pack-year standard may miss a significant proportion of high-risk individuals. Multidimensional risk stratification models that combine biomarkers, genetic risk scores, and imaging have become the core direction for the next generation of screening systems.

From Treatment to Prevention: A Structural TransformationThe larger trend reflected by this story is the global healthcare system’s paradigm shift from "late-stage treatment" to "early intervention." Lung cancer screening can reduce approximately 3 deaths per 1,000 people annually, with a cost-effectiveness ratio superior to that of breast and colorectal cancer screening. As population aging accelerates and the burden of smoking-related chronic diseases accumulates, the social return on investment in screening far outweighs the later-stage medical expenditures on targeted drugs or immunotherapy.

Of course, the transition is not without friction. Screening can lead to overdiagnosis and overtreatment, but conservative management protocols for early-stage lung cancer (especially ground-glass nodules) have been established in consensus. More importantly, screening must form a closed loop with smoking cessation interventions—after all, prevention is always better than early detection.

Long-Term Trends: A Foreseeable Future

It is foreseeable that lung cancer screening will see three major trends in the next decade: First, risk models will upgrade from "pack-year history" to "lifetime risk profiles," incorporating environmental exposure, genetic susceptibility, and history of chronic lung diseases; second, mobile CT and portable devices will penetrate into community pharmacies, corporate employee health stations, and even telemedicine vans; third, at the national level, screening coverage will become a core indicator for public health performance evaluation.

The man who was saved by a scan after quitting smoking for many years is one of thousands of individuals with "underestimated risk." His experience should not just be a news story, but a touchpoint for driving structural review of screening policies. In a world with limited medical resources, precisely directing resources to those most likely to benefit—this is both a call for efficiency and a matter of equity.